Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
CanSino Biologics develops and sells human vaccines, most notably for COVID-19, Ebola, and meningitis.
CanSino Biologics is a Chinese vaccine maker. It researches, develops, and manufactures vaccines for infectious diseases, then sells them to governments, public health programs, and other buyers. Its best-known product is a COVID-19 vaccine that was one of the first in China to win emergency approval. The company is based in Tianjin, and its shares trade in Hong Kong.

Its menu of shots covers several serious diseases. Besides the COVID-19 vaccine, CanSino makes an Ebola vaccine and meningitis vaccines, and it has been working on other candidates. The meningitis franchise has become a real commercial business, not just a lab project. Vaccines are a tough, slow business: a single product can take a decade and huge sums to develop, and regulators can say no at any stage. What matters most for CanSino is the pipeline and approvals. One hit vaccine can swing revenue sharply, and one setback can do the same in the other direction. Its COVID-19 shot put it on the map globally, with supply deals in several countries. But demand for COVID vaccines has cooled sharply worldwide, so the company's future depends on turning its other candidates into approved, sellable products.
The company spends heavily on research and manufacturing capacity, because vaccine making requires costly facilities and strict quality control. That spending is the price of admission if it wants a broader portfolio. The simple way to think about CanSino: it is a company that bets years of work on a few medical wins, then hopes regulators and buyers say yes.
Saved answer · last researched 16 Nov 2026